dynamic hyperinflation. We assessed the effects of NVA237 (glycopyrronium bromide), a once-daily long-acting muscarinic antagonist (LAMA), on exercise endurance in patients with moderate-to-severe COPD.

Methods Patients with COPD were randomised to a cross-over design of NVA237 50 µg or placebo once daily for 3 weeks, with a 14-day washout. The primary endpoint was endurance time during a submaximal constant-load cycle ergometry test (SMETT) on Day 21 of treatment. Endurance time after first dose, dynamic hyperinflation (inspiratory capacity [IC] at isotime during exercise), and morning trough FEV₁ and plethysmographic lung volumes were also measured.

Results 108 patients were randomised; mean age was 60.5 years, mean post-bronchodilator FEV₁ was 57.1% predicted. 88.0% completed the study. Endurance time on Day 21 significantly increased by 21% with NVA237 vs placebo; the effect was significant from Day 1, with an increase of 10%. Both dynamic IC at exercise isotime and trough FEV₁ showed significant and clinically relevant improvements from Day 1 that were maintained for the study duration (Abstract P254 table 1). This was accompanied by inverse decreases in residual volume and functional residual capacity (Abstract P254 table 1). Overall, the safety profile of NVA237 was similar to that of placebo.

Abstract P254 Table 1 NVA237 treatment effects vs placebo

	NVA237 (LS means, 95% CI)	PBO (LS means, 95% CI)	NVA237–placebo (LS means diff, 95% CI)	p Value
Endurance time (s)				
Day 1	490.9 (458.5 to 523.4)	447.78 (415.1 to 480.5)	43.1 (10.9 to 75.4)	<0.001
Day 21	505.6 (466.6 to 544.7)	416.70 (377.8 to 455.6)	88.9 (44.7 to 133.2)	<0.001
IC at isotime (l)				
Day 1	2.25 (2.18 to 2.31)	2.02 (1.96 to 2.08)	0.23 (0.17 to 0.28)	<0.001
Day 21	2.22 (2.15 to 2.29)	2.02 (1.95 to 2.09)	0.20 (0.13 to 0.28)	<0.001
Functional residual capacity (l) % predicted				
Day 1	4.41 (4.32 to 4.51)	4.77 (4.67 to 4.86)	−0.36 (−0.49 to −0.22)	—
Day 21	4.32 (4.22 to 4.42)	4.78 (4.68 to 4.87)	−0.46 (−0.58 to −0.33)	—
Residual volume (l)				
Day 1	3.49 (3.38 to 3.59)	3.92 (3.82 to 4.02)	−0.44 (−0.58 to −0.29)	—
Day 21	3.46 (3.36 to 3.55)	3.95 (3.86 to 4.05)	−0.50 (−0.63 to −0.36)	—
Total lung capacity (l)				
Day 1	7.01 (6.90 to 7.12)	7.08 (6.97 to 7.19)	−0.07 (−0.22 to −0.08)	—
Day 21	6.86 (6.75 to 6.97)	7.10 (6.99 to 7.21)	−0.25 (−0.39 to −0.10)	—
Specific airway conductance (Sec (−1)*kP)				
Day 1	0.68 (0.65 to 0.71)	0.41 (0.38 to 0.45)	0.26 (0.22 to 0.30)	—
Day 21	0.66 (0.63 to 0.70)	0.42 (0.39 to 0.46)	0.24 (0.19 to 0.29)	—
Trough FEV ₁ (l)				
Day 1	1.46 (1.43 to 1.49)	1.35 (1.31 to 1.38)	0.11 (0.06 to 0.16)	<0.001
Day 21	1.44 (1.40 to 1.48)	1.33 (1.29 to 1.37)	0.11 (0.06 to 0.16)	<0.001

Conclusion Once-daily NVA237 provided immediate and significant improvement in exercise endurance from Day 1. This was accompanied by sustained and significant improvements in IC at isotime, meaningful improvements in trough FEV₁, and sustained reductions of lung hyperinflation. There was an improvement in endurance time during the study period, suggesting that mechanisms beyond improved lung function play a part in superior exercise tolerance.

P255 **ATTAIN: TWICE-DAILY ACLIDINIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

doi:10.1136/thoraxjnl-2011-201054c.255

¹D Singh, ²P W Jones, ³E D Bateman, ⁴A Agusti, ⁵R Larmar, ⁵G de Miquel, ⁶C Caracta, ⁵E Garcia Gil. ¹Medicines Evaluation Unit, University of Manchester, Manchester, UK; ²St George's, University of London, London, UK; ³University of Cape Town, Cape Town, South Africa; ⁴Thorax Institute, Hospital Clinic, Barcelona, and CIBER Enfermedades Respiratorias and Fundació Caubet-Cimera, Barcelona, Spain; ⁵Almirall S.A., Barcelona, Spain; ⁶Forest Research Institute, New Jersey, USA

Introduction and Objectives The Phase III ATTAIN study investigated the effect of two twice daily doses of aclidinium bromide, a second-generation, long-acting muscarinic antagonist with low systemic activity, in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Methods In this 24-week, double-blind study, patients were randomised (1:1:1) to receive aclidinium (200 µg, 400 µg) or placebo, twice daily. The primary endpoint was change from baseline in trough forced expiratory volume in 1 second (FEV₁) at Week 24. Other study assessments at 24 weeks included: change from baseline in peak FEV₁; percentage of patients achieving a clinically meaningful improvement in St George's Respiratory Questionnaire total score and Transition Dyspnoea Index; COPD symptoms as assessed by the EXACT Respiratory Symptoms score; exacerbation rate based on two definitions (healthcare resource utilisation and EXacerbations of Chronic pulmonary disease Tool). Adverse events (AEs), clinical laboratory measures, vital signs and ECGs were also assessed.

Results A total of 819 patients were included in intention-to-treat (ITT) and safety populations. At Week 24, aclidinium 200 µg and 400 µg significantly improved trough FEV₁ from baseline compared with placebo (by 99 ml and 128 ml, respectively; both p<0.0001). Aclidinium was significantly superior to placebo at Week 24 for all other study assessments (Abstract P255 table 1). Aclidinium was well tolerated and the incidence of anticholinergic AEs was low and similar to placebo. Changes in laboratory tests, vital signs and ECGs were similar between all groups.

Abstract P255 Table 1 Study assessments at Week 24 (ITT population)

	Placebo twice daily n=273	Aclidinium 200 µg twice daily n=277	Aclidinium 400 µg twice daily n=269
Change from baseline in trough FEV ₁ vs placebo (ml) (±SE)	—	99*** (0.02)	128*** (0.02)
Change from baseline in peak FEV ₁ vs placebo (ml) (±SE)	—	185*** (0.02)	209*** (0.02)
Clinically meaningful improvement (≥1 unit) in TDI focal score (% patients)	45.5	53.3*	56.9**
Clinically meaningful improvement (≥4 units) in SGRQ total score (% patients)	39.5	54.9***	54.3***
E-RS total score (±SE)	−0.43 (0.53)	−3.59*** (0.52)	−4.08*** (0.53)
Exacerbation frequency, HCRU (rate ratio vs placebo) (95% CI)	—	0.72* (0.52 to 0.99)	0.67* (0.48 to 0.94)
Exacerbation frequency, EXACT (rate ratio vs placebo) (95% CI)	—	0.72* (0.55 to 0.94)	0.71* (0.54 to 0.93)

*p<0.05, **p<0.01, ***p<0.001 vs placebo.

ER-S, EXACT Respiratory Symptoms; EXACT, EXacerbations of Chronic pulmonary disease Tool; FEV₁, forced expiratory volume in 1 second; HCRU, healthcare resource utilisation; SGRQ, St George's Respiratory Questionnaire; TDI, Transition Dyspnoea Index.

Conclusion Acclidinium 200 µg and 400 µg twice daily provided clinically meaningful improvements in bronchodilation, health status, symptoms, breathlessness and exacerbation rate. Acclidinium was well tolerated with a similar safety profile for both doses; the incidence of AEs was similar to placebo.

Funding This study was supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc., New York, USA.

P256 ACLIDINIUM BROMIDE: A PHASE IIB, DOSE-FINDING STUDY

doi:10.1136/thoraxjnl-2011-201054c.256

¹D Singh, ²H Magnussen, ²A Kirsten, ³S Mindt-Pruefert, ⁴C Caracta, ⁵D Jarreta, ⁵E Garcia Gil. ¹Medicines Evaluation Unit, University of Manchester, Manchester, UK; ²Pulmonary Research Institute, Hospital Grosshansdorf, Grosshansdorf, Germany; ³Klinische Forschung Hamburg GmbH, Hamburg, Germany; ⁴Forest Research Institute, New Jersey, USA; ⁵Almirall S.A., Barcelona, Spain

Introduction and Objectives Acclidinium bromide, a second-generation, long-acting muscarinic antagonist with low systemic activity, is in clinical development for the twice daily maintenance treatment of chronic obstructive pulmonary disease (COPD). This Phase IIB study investigated the dose-response bronchodilation of acclidinium twice daily vs placebo and an active control (formoterol 12 µg twice daily) in patients with moderate to severe COPD.

Methods In this double-blind, double-dummy, cross-over study, 79 patients received 7-day treatments of acclidinium 100 µg, 200 µg and 400 µg, formoterol 12 µg and placebo twice daily over five treatment periods separated by a 7-day washout. The primary endpoint was change from baseline in normalised forced expiratory volume in 1 second (FEV₁) area under the curve (AUC)₀₋₁₂ at Day 7. Other efficacy assessments included change from baseline at Day 7 in normalised FEV₁ AUC₀₋₂₄ and morning pre-dose (trough) and peak FEV₁. Adverse events (AEs) were reported throughout the study.

Results Acclidinium provided dose-dependent bronchodilation compared with placebo as assessed by change from baseline in normalised FEV₁ AUC₀₋₁₂ and FEV₁ AUC₀₋₂₄ at Day 7 (Abstract P256 table 1). The bronchodilation provided by acclidinium 400 µg during the first 12 h was comparable to the active control, formoterol 12 µg. Acclidinium improved morning pre-dose trough FEV₁ and peak FEV₁ after 7 days compared with placebo; the 400 µg dose was most comparable to formoterol 12 µg. Acclidinium was well tolerated; the safety profile of all doses was comparable to that of placebo.

Abstract P256 Table 1 Adjusted mean (SE) change from baseline (L) on Day 7

	Acclidinium 100 µg	Acclidinium 200 µg	Acclidinium 400 µg	Formoterol 12 µg	Placebo
Normalised FEV ₁ AUC _{0-12h}	0.128* (0.022)	0.151* (0.022)	0.183* (0.022)	0.185* (0.022)	-0.026 (0.022)
Normalised FEV ₁ AUC _{0-24h}	0.089* (0.021)	0.100* (0.021)	0.133* (0.021)	0.163* (0.020)	-0.062 (0.021)
Morning pre-dose FEV ₁	0.081* (0.023)	0.089* (0.023)	0.130* (0.023)	0.123* (0.023)	-0.025 (0.023)
Morning peak FEV ₁	0.287* (0.023)	0.299* (0.023)	0.340* (0.023)	0.344* (0.023)	0.098 (0.023)

*p<0.0001 vs placebo.

Conclusion A dose-dependent bronchodilation was observed with acclidinium twice daily. The bronchodilation provided by the highest dose of acclidinium (400 µg) twice daily was comparable to formoterol 12 µg twice daily. The safety profile of acclidinium was similar to placebo, with no dose-dependent AEs observed.

Funding This study was supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc., New York, USA.

P257 EFFECTS OF EXTRA-FINE INHALED AND ORAL CORTICOSTEROIDS ON ALVEOLAR NITRIC OXIDE IN COPD

doi:10.1136/thoraxjnl-2011-201054c.257

P M Short, P A Williamson, B J Lipworth. *Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK*

Introduction and Objectives Alveolar nitric oxide or (CA_{NO}), has been used as a surrogate marker of distal airway inflammation, which is important in COPD. Coarse particle inhaled corticosteroids (ICS) have been shown not to suppress CA_{NO}. We evaluated whether extra-fine particlesize inhaled corticosteroids (HFA-BDP) or systemic oral corticosteroids could suppress CA_{NO} in COPD.

Methods COPD patients with a smoking pack history >15 years, FEV₁/FVC ratio <0.7, FEV₁<80% predicted with small airways inflammation characterised by CANO >2 ppb underwent a double-blind randomised controlled crossover trial with an open label systemic steroid comparator. Following a 2 wk steroid washout period, patients were randomised to 3 weeks, 100 mcg HFA-BDP twice daily and then 3 weeks 400 mcg HFA-BDP twice daily or matched placebos with subsequent crossover. All patients then received 1 week open-label, 25 mg/day prednisolone. Spirometry, bodyplethysmography, impulse oscillometry, plasma cortisol and exhaled nitric oxide were recorded. CA_{NO} was corrected for axial diffusion.

Results 16 patients completed per protocol. Compared to respective placebo there were no significant differences seen with either dose of HFA-BDP. Oral prednisolone caused a significant reduction in FE_{NO} and J'aw_{NO} but not CA_{NO}. Plasma cortisol was significantly suppressed by oral prednisolone compared to all other treatments. There was no suppression seen with HFA-BDP at either dose verses placebo.

Conclusions While CA_{NO} remains a biomarker of interest in COPD, it is not suppressed by systemic or extra-fine particle ICS. Hence CA_{NO} is unlikely to be a useful marker for monitoring response of small airway disease to therapies in COPD.

P258 ROLE OF 7-DAY AND 14-DAY COURSES OF ORAL PREDNISOLONE TREATMENT IN ACUTE EXACERBATION OF COPD

doi:10.1136/thoraxjnl-2011-201054c.258

S M Abdullah Al Mamun, S Rahman. *Sher E Bangla Medical college, Barisal, Bangladesh*

Purpose The purpose of this study was to compare the efficacy of 7-day and 14-day courses of oral prednisolone treatment in patients with acute exacerbation of COPD with FEV₁<50% predicted.

Methods It was a prospective randomised, single blind study in a tertiary care centre, the study patients were included and randomised into two groups: 7-day group received oral prednisolone 30 mg/day for 7 days, and 14-day group was administered the same dosage of oral prednisolone for 14 days. There was no significant difference between the groups for age, smoking pack years, symptoms of COPD in years, no. of previous exacerbations, blood eosinophilia, baseline FEV₁, and FVC levels. One patient from 7-day group developed pneumothorax and one from 14-day group died of acute Myocardial Infarction.

Results Both groups showed significant improvements of FEV₁ and FVC on D-1, D-3, D-5, D-7, D-10 and Day-14 from the baseline (7-day group, p=0.0001, 0.0001, 0.008, 0.009, 0.008, 0.011 and 14-day group, p=0.000, 0.000, 0.000, 0.000, 0.000, 0.000) and the improvement of FVC is also significant in both the groups, but there was no significant difference of improvement between the two groups on day-7 and day-14 (p=0.100, 0.079). There was also significant improvement of symptom score from baseline on day-7 and day-14, but no significant difference of improvement between two groups.